$3.390
-0.171 (-5.04%)Zum Schluss
NNBR-News
NNBR-Events
NN Raises FY26 EBITDA Outlook to $65M
Consensus $464.87M. Raises FY26 adjusted EBITDA view to $55M-$65M from $50M-$60M. Bevis concluded, "We are encouraged by the business results and refinancing results that we have delivered this year. We see continuation into the second half. We believe the second half of 2026 and 2027 will continue to benefit from our multi-year strategic growth focus and operational execution processes. Our 5 pillar growth program is delivering strong results. We are also reengineering our balance sheet right now, reducing leverage and reducing rates. We have a goal to refinance the current securities and convert NN to normal credit statistics. We believe that we are just at the beginning of common stock value-creation and it is an exciting time at NN."
NN Reports Q2 Revenue of $128.74M
Reports Q2 revenue $128.74M, consensus $116.09M. Harold Bevis, President and Chief Executive Officer, said, "NN delivered strong financial performance in the second quarter with record results in many areas. Additionally, after the quarter ended, we implemented a game-changing improvement to our balance sheet."
NN, Inc. Enters U.S. Firearm Components Contract Manufacturing Market
NN, Inc. announced entry into a brand-new market segment for the company. The company has entered the contract manufacturing industry for firearm components in the United States market. NN has entered into a contract manufacturing agreement to mass produce completed firearms products for a provider of firearms products in the United States. This new product category is included within NN's business growth program in Defense & Electronics. This new business begins in Q3 and will continue ramping up through 2028. This new business is expected to add between $12M-$15M in sales.
Selling Stockholders Plan to Sell 24.51M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 24.51M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
NN, Inc. Medical Products Business Secures $25M Orders
NN, Inc. announced that its medical products business has qualified and received initial purchase orders to manufacture critical components for a leading robotic-assisted surgery platform. The milestone follows a successful quality audit at the company's Kentwood, Michigan facility. The new customer has released first purchase orders with immediate delivery and ramp-up requirements. Following this contract win, the company's medical new business pipeline has increased by approximately $25M to around $75M overall, out of a total corporate new business pipeline of more than $750M. "This is a milestone event for NN's medical products growth program and a direct payoff on the investments we have made over the last three years to establish a premier presence in this medical market," said Harold Bevis, president and CEO of NN, Inc. "Passing this full facility quality audit and securing our first newly associated purchase orders to make precision components for a leading robotic surgery platform is a good step forward for NN."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.